Disparities in access to anti‐vascular endothelial growth factor treatment for neovascular age‐related macular degeneration
Clinical and Experimental Ophthalmology2016Vol. 45(2), pp. 143–151
Citations Over TimeTop 21% of 2016 papers
Abstract
A large proportion of incident nvAMD is not treated with anti-VEGF. Not receiving treatment is more likely in regional or remote areas and areas with fewer service providers. Not speaking English at home may further limit access. Service delivery models for more equitable service provision are needed.
Related Papers
- → Age-related macular degeneration(2023)400 cited
- → PHARMACOGENOMICS OF RESPONSE TO ANTI-VEGF THERAPY IN EXUDATIVE AGE-RELATED MACULAR DEGENERATION(2015)36 cited
- → Pharmacotherapy of age-related macular degeneration(2008)18 cited
- → Barriers to care in neovascular age-related macular degeneration: Current understanding, developments, and future directions(2023)8 cited
- Real-world UK NHS outcomes of a switch to Aflicercept from Ranibizumab in Neovascular age related macular degeneration (nvAMD).(2015)